Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth

Yong, Li; Cai, Quanyu; Li, Wanhu; Feng, Feiling; Yang, Liang

doi:10.1016/j.bbrc.2018.08.174

Cited by 22 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs are a group of noncoding transcripts whose length is over 200 nucleotides, with limited capacities in coding proteins [6]. Accumulating evidence suggested that lncRNAs had played vital roles in a broad scale of biological movements among cancers, including apoptosis, metastasis and proliferation as well as chemoresistance [7][8][9]. Thus, it was exceedingly important to comprehend the pathology of GC by delving into potential mechanism of lncRNAs.…”

Section: Introductionmentioning

confidence: 99%

LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703

Zhang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: The crucial role of long non-coding RNAs (lncRNAs) has been certified in human cancers. The lncRNAs with abnormal expressions could act as tumor inhibitors or oncogenes in the advancement of tumors. LBX2-AS1 was once reported to accelerate esophageal squamous cell carcinoma. Nonetheless, its function in gastric cancer (GC) remained a riddle. Methods: RT-qPCR was used to examine the expression of NFIC/LBX2-AS1/miR-491-5p/ZNF703 in GC cell lines. The functions of LBX2-AS1 in GC were appraised by colony formation, EdU, flow cytometry analysis, transwell and wound healing assays. Luciferase reporter, ChIP and RNA pull down assays were utilized to evaluate the interactions among genes. Results: LBX2-AS1 was up-regulated in GC cell lines. Knockdown of LBX2-AS1 repressed the proliferative, migratory, and invasive abilities of GC cells. Moreover, LBX2-AS1 was transcriptionally activated by NFIC. And LBX2-AS1 could bind with miR-491-5p. Besides, miR-491-5p depletion or ZNF703 upregulation could counteract the repressing effects of LBX2-AS1 silence on GC progression. Conclusion: In a word, LBX2-AS1 up-regulated by NFIC promoted GC progression via targeting miR-491-5p/ZNF703, implying LBX2-AS1 was an underlying treatment target for GC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703

Zhang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Conversely, lncRNA may positively affect the expression of oncogenic regulators, either directly or indirectly. Thus, epigenetically-induced lncRNA-1 (EPIC1) was reported to promote CCA cell growth and cancer progression by physically interacting with MYC oncogene and possibly acting as a guide to direct MYC onto its target A c c e p t e d m a n u s c r i p t 5 genes involved in cell cycle progression 16 . Interestingly, LINC01296 lncRNA was demonstrated to stabilize MYCN oncogene by sponging microRNA-5095, which naturally targets MYCN mRNA for degradation 17 .…”

Section: Introductionmentioning

confidence: 99%

“…CRNDE, UCA1, TUG1) was reported to correlate with clinical progression (e.g. tumor grade, lymph node metastasis, TNM stage) and was identified as risk factors for an unfavorable overall survival (OS) in iCCA 16,18,[20][21][22][23] .…”

Section: Introductionmentioning

confidence: 99%

Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma

Angenard

Merdrignac

Louis

et al. 2019

Digestive and Liver Disease

View full text Add to dashboard Cite

Background: Intrahepatic cholangiocarcinoma (iCCA) is a deadly cancer worldwide associated with an increased incidence, limited therapeutic options and absence of reliable prognostic biomarkers. Long non-coding RNAs (lncRNA) emerge as relevant biomarkers in cancer being associated with tumor progression. However, lncRNA have been poorly investigated in iCCA. Aim: To identify lncRNA significantly associated with the survival of patients with iCCA after tumor resection for curative intent. Methods: Gene expression profiling and Q-RT-PCR were performed from a cohort of 39 clinically well-annotated iCCA. Univariate Cox proportional hazards model with Wald Statistic was used to identify lncRNA significantly associated with overall (OS) and/or disease-free (DFS) survival. Results: A signature made of 9 lncRNA was identified to be significantly (P<0.05) associated with OS and DFS, including 4 lncRNA (lnc-CDK9-1, XLOC_l2_009441, CDKN2B-AS1, HOXC13-AS) highly expressed in poor prognosis iCCA and 5 lncRNA (lnc-CCHCR1-1, lnc-AF131215.3.1, lnc-CBLB-5, COL18A1-AS2, lnc-RELL2-1) highly expressed in better prognosis iCCA. We further validated CDKN2B-AS1 (ANRIL) as a poor prognosis biomarker, not only in iCCA, but also in hepatocellular carcinoma, kidney renal clear cell carcinoma and uterine corpus endometrial carcinoma. Conclusions: We report a prognosis lncRNA signature in iCCA and the clinical relevance of CDKN2B-AS1 (ANRIL) overexpression in several cancers.

show abstract

“…Li et al confirmed the upregulation of EPIC1 also in BTC tumor tissue samples [63]. To investigate the molecular oncogenic effects of EPIC1 in BTC, RNA interference experiments were performed and showed that knockdown of EPIC1 resulted in apoptosis and suppression of BTC cell growth as well as colony formation [63].…”

Section: Epic1mentioning

confidence: 99%

Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review

Bekric

Neureiter

Ritter

et al. 2020

JCM

View full text Add to dashboard Cite

The term long non-coding RNA (lncRNA) describes non protein-coding transcripts with a length greater than 200 base pairs. The ongoing discovery, characterization and functional categorization of lncRNAs has led to a better understanding of the involvement of lncRNAs in diverse biological and pathological processes including cancer. Aberrant expression of specific lncRNA species was demonstrated in various cancer types and associated with unfavorable clinical characteristics. Recent studies suggest that lncRNAs are also involved in the development and progression of biliary tract cancer, a rare disease with high mortality and limited therapeutic options. In this review, we summarize current findings regarding the manifold roles of lncRNAs in biliary tract cancer and give an overview of the clinical and molecular consequences of aberrant lncRNA expression as well as of underlying regulatory functions of selected lncRNA species in the context of biliary tract cancer.

show abstract

Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth

Cited by 22 publications

References 15 publications

LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703

LBX2-AS1 up-regulated by NFIC boosts cell proliferation, migration and invasion in gastric cancer through targeting miR-491-5p/ZNF703

Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma

Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review

Contact Info

Product

Resources

About